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Abstract
Background: Dysregulation of the common stress responsive transcription factor ATF3 has been causally linked to
many important human diseases such as cancer, atherosclerosis, infections, and hypospadias. Although it is believed
that the ATF3 transcription activity is central to its cellular functions, how ATF3 regulates gene expression remains
largely unknown. Here, we employed ATF3 wild-type and knockout isogenic cell lines to carry out the first
comprehensive analysis of global ATF3-binding profiles in the human genome under basal and stressed (DNA
damage) conditions.
Results: Although expressed at a low basal level, ATF3 was found to bind a large number of genomic sites that are
often associated with genes involved in cellular stress responses. Interestingly, ATF3 appears to bind a large portion
of genomic sites distal to transcription start sites and enriched with p300 and H3K27ac. Global gene expression
profiling analysis indicates that genes proximal to these genomic sites were often regulated by ATF3. While DNA
damage elicited by camptothecin dramatically altered the ATF3 binding profile, most of the genes regulated by
ATF3 upon DNA damage were pre-bound by ATF3 before the stress. Moreover, we demonstrated that ATF3 was
co-localized with the major stress responder p53 at genomic sites, thereby collaborating with p53 to regulate p53
target gene expression upon DNA damage.
Conclusions: These results suggest that ATF3 likely bookmarks genomic sites and interacts with other transcription
regulators to control gene expression.
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Background
The development of human diseases is often accompanied
by changes in the gene expression landscape. Regulated
mainly at the transcription level, gene expression is tightly
controlled by transcription factors (TF) that bind not only
promoters proximal to transcription start sites (TSS), but
also distal cis-regulatory elements (i.e., enhancers) that are
far removed from TSS [1, 2]. Genome-wide profiling stud-
ies using chromatin immunoprecipitation coupled with
sequencing (ChIP-seq) have identified thousands of func-
tional/active enhancers that are either bound by the tran-
scriptional co-activator p300, or characterized by their
association with high levels of H3 K27 acetylation
(H3K27ac) [3–5]. These enhancers often carry binding sites
for more than one TF, which interact with the basal tran-
scription machinery associated with core promoters to
regulate gene transcription [2]. Very often, TFs also recruit
chromatin-modifying enzymes to convert the chromatin to
a state permissive for transcription. Pioneer transcription
factors (e.g., FoxA1, PU.1), for example, are often the first
to engage in a regulatory chromatin region upon stimula-
tion, and enhance transcription by remodeling the local
chromatin to make it competent for other TFs to bind [6].
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While global profiling of genomic sites competent for
TF binding is imperative for the understanding of TF
functions, such work has also become increasingly im-
portant for defining disease etiologies, as mutations in
cis-regulatory elements are frequently found to be asso-
ciated with human diseases (e.g., cancer) by whole-
genome sequencing studies [7].
Activating transcription factor 3 (ATF3) is a member of
the ATF/CREB family of transcription factors involving in
many important human diseases including cancer [8–11],
atherosclerosis [12], infections [13], cardiac hypertrophy
[14], and hypospadias [15]. The contributions of ATF3 to
these diseases are often owing to its rapid induction by a
wide-range of cellular stresses (e.g., DNA damage, oxida-
tive stress, and endoplasmic reticulum (ER) stress), leading
to activation of cellular signaling required for the mainten-
ance of cell homeostasis. Indeed, while it binds and acti-
vates the tumor suppressor p53 in response to oncogenic
challenges (e.g., DNA damage and Pten inactivation) [11,
16], ATF3 also engages in the immune response by inter-
acting with NF-κB and repressing expression of proinflam-
matory cytokines induced by the toll-like receptor 4 [17].
Similarly, ATF3 induced by reactive oxygen species causes
high susceptibility to secondary infections by repressing
interleukin 6 (IL-6) expression during sepsis-associated im-
munosuppression [13]. Like other ATF/CREB transcription
factors, ATF3 regulates transcription by binding the canon-
ical ATF/CRE cis-regulatory element (5’-TGACGTCA-3’)
or the similar AP-1 site (5’-TGA(C/G)TCA-3’) via its basic
region-leucine zipper domain (bZip) [18]. Although an
over-simplified model suggests that ATF3 homodimers and
heterodimers (with other bZip proteins) repress and induce
gene expression, respectively [19], the mechanism by which
ATF3 regulates transcription remains largely unknown.
Interestingly, although the structures of the bZip domains
are highly similar allowing the largely diversified ATF/
CREB proteins to bind the same cis-regulatory elements,
the genes regulated by ATF3 are distinct from those con-
trolled by its family members. ATF3 and ATF6, for in-
stance, regulate expression of proapoptotic genes and genes
involved in protein folding and ER quality control upon ER
stress, respectively [20]. As recent evidence supports that
ATF3 engages in a complex protein-protein interaction net-
work involving many TFs and transcription co-regulators
[16, 21, 22], it is likely that the interactions with other nu-
clear proteins define the genomic sites where ATF3 binds
and the transcription programs that ATF3 regulates.
Characterization of genome-wide ATF3 binding sites would
thus lead to further elucidation of the ATF3 interaction net-
work and a better understanding of how ATF3 regulates
expression of disease-associated genes.
In this study, we present the first comprehensive ana-
lysis of ATF3 binding profiles in the human genome. We
show that ATF3 bound a large portion of active enhancers
characterized by p300 binding and enriched with K27
acetylated histone H3 (H3K27ac) under the basal condi-
tion where ATF3 was expressed at a very low level. While
the expression of genes proximal to these enhancers
tended to be regulated by ATF3, ATF3 was co-localized
with p53 and regulated p53-target gene expression in re-
sponse to DNA damage. Our results thus suggest that
ATF3 likely bookmarks genes for transcriptional regula-
tion under basal and stressed conditions.
Results
Genome-wide mapping of ATF3 binding sites using
isogenic cell lines
To profile global ATF3-binding sites, we first employed
a genome-editing approach based on recombinant ade-
noassociated viruses (rAAV) to generate a cell line in
which ATF3 expression was knocked out. Towards this
end, we constructed an AAV targeting vector containing
left (LA) and right homology arms (RA) flanking the
exon 3 of the ATF3 gene, and introduced the vector into
HCT116 human colon cancer cells via rAAV infections
[23]. Homologous recombination between the homology
arms and the ATF3 fragments resulted in the insertion
of a selection gene (TK-neo) into an ATF3 allele. A small
deletion (22 bp) in the exon 3 was subsequently gener-
ated by Cre-mediated excision of the selection gene
(Fig. 1a). The same strategy was employed to target the
second ATF3 allele, generating a cell line (ATF3-KO) in
which ATF3 expression was disrupted. We confirmed
that ATF3 was not expressed and ATF3 expression was
not induced by camptothecin (CPT) - a DNA-damaging
agent - in the knockout cells (Fig. 1b).
We thus subjected the wild-type (ATF3-WT) cells and
the knockout cells to chromatin immunoprecipitation
using an ATF3 antibody. Precipitated DNAs were then la-
beled and subjected to next-generation sequencing and se-
quencing reads were mapped to human genome and
analyzed for enrichment. Although ATF3 was expressed at
a low level (Fig. 1b, lane 1), we identified 33,681 high-
confident ATF3-binding peaks in the sample derived from
ATF3-WT cells (Fig. 1c). Out of them, a majority of peaks
(32,058) were ATF3 specific, as they were not found in the
ATF3-KO cells (Fig. 1c and d). A few examples of ATF3
peaks were shown in Fig. 1e. Of note, like a majority of
identified sites, these ATF3 peaks were found only in the
ATF3-WT sample but not in the ATF3-KO sample
(Fig. 1e). Consistent with an early result that ATF3 re-
presses its own expression [24], we found that ATF3
strongly bound its own promoter (Fig. 1e). Using quantita-
tive PCR (qPCR) to examine samples from an independ-
ent ChIP experiment, we confirmed that ATF3 bound to
all of the tested genomic sites identified by ChIP-seq
(Fig. 1f). Again, ATF3 bound to its own promoter in the
ATF3-WT cells but not in the knockout cells (Fig. 1g).
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The strengths of ATF3 binding to these sites measured by
ChIP-qPCR were well correlated with the ChIP-seq scores
(R = 0.6328), demonstrating high reproducibility and reli-
ability of our ChIP-seq data.
Global ATF3-binding profile and motif analysis
The 32,058 ATF3-specific peaks were annotated to
10,262 unique genes. We analyzed the distribution of
these binding sites relative to TSS in the human genome.
Consistent with the ATF3’s role as a transcription factor,
about one fifth (19.4 %) of the ATF3 peaks were local-
ized in promoters, which was defined as regions that
were ±2 kb surrounding TSS (Fig. 2a). Given that only a
small portion of DNA in the whole genome can be de-
fined as promoters, these results indicate that ATF3
were enriched in promoters. However, ATF3 also bound
Fig. 1 ATF3 binding profiling using isogenic HCT116 cells. a rAAV-mediated genome editing was applied to generate ATF3-knocked out HCT116
cells. rAAV-mediated homologous recombination led to insertion of the AAV targeting vector into ATF3 exon 3. A deletion of 22 bp was generated in
one ATF3 allele after Cre-mediated excision of the Neo selection gene. LA and RA, left and right homology arms; ITR, inverted terminal repeat; KO,
knockout. b ATF3 expression was completely abolished in ATF3-KO cells. Indicated cells were treated with 1.5 μM of CPT and subjected to Western
blotting. c Venn diagram showing ATF3-binding peaks in ATF3 wild-type (ATF3-WT) and knockout (ATF3-KO) cells. d Heatmap and intensity plots
showing ATF3 peaks in ATF3 WT and KO cells. e Representative genome browser views of ATF3 peaks. ATF3 peaks near ATF3, STK40, HYI, SPRY1, and
UTP23 were shown for both ATF3-WT and KO cells. f, g ChIP-qPCR was used to validate ATF3 binding to representative genome sites that were
referred to as the names of their annotated genes. NR, no-binding control region. Error bars represent SD for three replicate measurements. h The
binding intensity determined by independent ChIP-qPCR assays was correlated with ChIP-seq scores of peaks tested in (f) and (g)
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genomic regions far removed from TSS (Fig. 2a), sug-
gesting that ATF3 also likely regulates transcription via
long-range interactions. Gene Ontology (GO) analysis of
the top 600 annotated genes with high binding scores re-
vealed that ATF3 preferably bound to regulatory elements
for genes involving in biological processes such as cellular
response to stress, cell cycle arrest and intracellular
signaling cascade, as well as pathways such as p53 signal-
ing pathway (Fig. 2b). Interestingly, “cellular response to
stress” and “p53 signaling pathway” turned out to be
the top GO terms for the ATF3-bound genes, consist-
ent with the well-established roles that ATF3 plays in
regulating cellular stress responses and the p53 path-
way [16, 18].
Fig. 2 Global ATF3-binding profile under the basal condition. a A pie chart showing distribution of ATF3 binding sites relative to annotated
genes. b 600 annotated genes with top peak scores were used for DAVID GO analysis. GO biological process (BP) terms and KEGG pathway terms
are shown. c Top motifs identified in the ATF3 binding sites. d Schematic showing relative abundance and overlaps of the three known ATF3
binding motifs. The numbers are peak numbers. e The binding of ATF3 to the ATF/CRE motif appeared to be stronger than the AP-1 motif.
Student t-test. f A table showing top motifs after combining motifs with same/similar sequences. g Venn diagram showing overlaps of CTCF,
GATA3, and TEAD motifs with the ATF3 motif
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We also searched the ATF3 binding sites for known
TF binding motifs using the Homer de novo motif dis-
covery software. A total of 140 motifs were identified
with a p value smaller than 0.01. With only one exception
(CEBP:AP1 motif), the top 12 identified motifs contained
either the canonical ATF/CRE sequence (i.e., 5’-
TGACGTCA-3’) or the AP-1 sequence (i.e., 5’-TGASTCA-
3’, S = C/G) (Fig. 2c). As C/EBP harbors a bZip domain that
can mediate dimerization with other bZip proteins includ-
ing ATF3 [25], it might be that ATF3 bound the CEBP:AP1
motif through dimerization with C/EBP. Overall, 81.7 % of
ATF3 binding sites contain an element predicted to be
bound by ATF3 - collectively referred to as the ATF3 motif
hereafter (Fig. 2d) - suggesting that ATF3 directly binds
genomic DNA in most cases. Interestingly, although more
ATF3 peaks contained the AP-1 motif (Fig. 2e), the bind-
ing affinity of ATF3 to the canonical ATF/CRE element
appeared to be higher than that for ATF3 binding to the
AP-1 element (Fig. 2e). In addition to these known ATF3
binding motifs, other top ATF3 binding motifs (i.e.,
Enrichment > 2) include GATA3, CTCF, TEAD, and Sp1,
which was presented in 7.7 %, 5.6 %, 14.8 %, and 6.5 % of
ATF3 peaks, respectively (Fig. 2f). Although these ATF3-
binding peaks often contain a known ATF3 motif (Fig. 2g),
ATF3 might also bind these motifs through interacting
with corresponding TFs. Indeed, ATF3 has been shown to
interact with Sp1 [26].
ATF3 globally binds active enhancers enriched with p300
and H3K27ac
As ATF3 bound genomic sites far removed from TSS, we
sought to determine whether these sites are coincided with
active enhancers that are often marked by p300 binding
and flanked with high levels of H3K27ac [3–5]. Towards
this end, we acquired p300, H3K27ac, H3K4me1, and
H3K4me3a ChIP-seq data (HCT116 cells) from the Gene
Expression Omnibus (GEO) database GSE51176 and
GSE38447 [27, 28]. We first examined the ATF3 peaks in
the Genome Browser, and found that ATF3 bound to many
sites that were also bound by p300 and flanked by regions
with high levels of H3K27ac (Fig. 3a), suggesting that ATF3
bound to active enhancers. Indeed, unbiased statistics ana-
lysis revealed that up to 27.5 % of ATF3 peaks were over-
lapped with p300 peaks, and 37 % of p300 peaks were
bound by ATF3 (Fig. 3b). Intensity plots also show that
p300 was globally co-localized with ATF3 and that the
H3K27ac histone marker surrounded the ATF3/p300 peaks
as expected (Fig. 3c). We segregated the ATF3 peaks into
proximal sites (within 2 kb) and distal sites (>2 kb) based
on their distances to TSS, representing H3K4me3-enriched
promoters and H3K4me1-enriched enhancers, respectively
(Fig. 3d). The intensity plots revealed that it was the distal
sites, but not the proximal sites, that were coincided with
p300 binding events (Fig. 3d). Using qPCR, we validated
that p300 bound to all of the tested ATF3 binding sites in
an independent ChIP experiment (Fig. 3e). Similarly, the
enrichment of H3K27ac in these ATF3 sites was also vali-
dated (Fig. 3f). Of note, as p300 is not the only enzyme that
can acetylate H3 at the K27 site, the H3K27ac level was not
strictly correlated with the p300 level in some genome sites.
Taken together, our results have revealed that a large por-
tion of ATF3 bound active enhancers.
ATF3-regulated gene expression correlates with ATF3
enhancer binding
An interesting question surfaced as to how ATF3 binding
to genomic sites regulates gene expression. To address this
question, we subjected the ATF3-wildtype and knockout
cells to cDNA microarray assays. Although ATF3 bound to
10,262 genes, only 1,087 unique genes, including several
known ATF3 targets (i.e., ASNS) [29], were differentially
expressed between the WT and KO cells (FDR < 0.05,
Additional file 1: Figure S1A and S1B). Among these genes,
630 (60 %) were bound by ATF3 and thus more likely to be
directly regulated by ATF3 (Fig. 4a). Roughly equal num-
bers of genes was either activated or repressed by ATF3
(Fig. 4a), suggesting that ATF3 can function as both a tran-
scription repressor and a transcription activator. In line
with the reported tumor suppressor role in colon cancer
[30, 31], ATF3 appeared to induce expression of genes in-
volving in mitosis and stress responses while repressing
genes regulating vasculature development, migration, and
apoptosis (Additional file 1: Figure S1C). We validated 7
differentially-expressed genes by quantitative RT-PCR
(Fig. 4b) and their binding by ATF3 by independent ChIP-
qPCR assays (Fig. 4c and d). Interestingly, although ATF3
were often reported to regulate gene expression by binding
to a ATF3 motif localized in promoters, only 15 % (95/630)
of the ATF3-regulated genes identified herein were bound
by ATF3 exclusively at their promoters (proximal genomic
regions) (Fig. 4e). The rest of genes either were bound by
ATF3 exclusively at distal regions (57 %, or 361/630), or at
both promoters and distal regions (28 %, or 95/630)
(Fig. 4e). These results suggest that ATF3 could regulate
gene expression by binding to distal cis-regulatory ele-
ments localized in active enhancers. Indeed, except
MAL2, all other validated ATF3-target genes were
bound by ATF3 at distal regions overlapped with p300
peaks (Fig. 4f ). Of the 535 genes containing distal
ATF3-binding sites, 354 (66.2 %) were associated with
active enhancers enriched with p300 and bound by
ATF3 (Fig. 4g). Interestingly, ATF3-repressed genes ap-
peared to be more likely to harbor distal ATF3 regula-
tory elements than ATF3-activated genes (Additional
file 1: Figure S1D), although the TF motifs contained in
the ATF3-binding sites in these two groups of genes
were similar (Additional file 1: Figure S1E).
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DNA damage alters the ATF3-binding landscape for gene
regulation
As a common stress sensor, ATF3 may regulate cellular
stress responses by altering the gene expression landscape.
To understand how cellular stresses alter genome-wide
ATF3 binding profile for transcriptional regulation, we
subjected HCT116 cells treated with CPT for ChIP-seq as-
says. As CPT could increase the ATF3 expression level
(Fig. 1b) [32], it was not surprising that the DNA-
damaging treatment increased the number of ATF3-
binding sites to 70,231 (Fig. 5a) – one fold more than that
under the basal condition. However, we found that a large
number of sites (7,172, 21.3 %) bound by ATF3 under the
basal condition were not detected after the CPT treatment
(Fig. 5a and b, “WT-only”). ATF3 bound these sites more
weakly than the remained sites (Fig. 5b, “WT-only” vs.
“Shared” peaks, p = 7.46e-05). Of the “shared” peaks, DNA
damage increased ATF3 binding to 13,253 sites but
decreased its binding to the rest 13,256 sites (Additional
file 1: Figure S2A). Interestingly, while the CPT-increased
sites appeared to be bound by ATF3 more strongly than
the CPT-decreased sites under the basal condition
(Fig. 5c), the increased sites were also often bound by
p300, or enriched with H3K4me1, suggesting that DNA
damage promoted ATF3 to bind to active enhancers
(Fig. 5c). In contrast, CPT tended to decrease ATF3 bind-
ing to those sites localized in promoters and thus often
flanked by a high level of H3K4me3 [33] (Fig. 5c).
Fig. 3 ATF3 globally binds genomic sites enriched with p300 and H3K27ac. a Genome browser views showing co-localization of ATF3 with p300
and H3K27ac in several representative genomic sites. b Venn diagram showing overlaps between ATF3 peaks and p300 peaks. c Intensity plot
showing co-localization of ATF3 with p300 and H3K27ac. d Venn diagram showing overlaps between p300 distal peaks (active enhancers) and
ATF3 peaks. e ChIP-qPCR validation of p300 binding to the ATF3 binding sites. HCT116 cells were subjected to ChIP using a p300 antibody.
Precipitated DNA was quantitated using qPCR. f H3K27ac was enriched in the ATF3-binding sites. ChIP-qPCR was carried out to determine
H3K27ac levels in the ATF3-binding sites
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Consistent with these observations, although DNA dam-
age did not significantly change the overall genome distri-
bution and motif composition of the ATF3 binding sites
(Additional file 1: Figure S2B and S2C), it promoted ATF3
to bind to the sites distal to TSS (Fig. 5d). Similarly, DNA
damage increased the number of sites bound by both
ATF3 and p300, and the number of these ATF3-bound ac-
tive enhancers was increased from 37 % under the basal
condition to 57.6 % upon stress (Fig. 5e). Interestingly, the
new sites bound by ATF3 after DNA damage (“CPT only”
in Fig. 5b) had weaker ATF3-binding affinities than the sites
bound by ATF3 under the basal condition (p = 1.73e-07,
comparing “CPT only” vs “Shared” peaks in Fig. 5b), but
had stronger affinities than those lost peaks (p = 0.000345,
“CPT only” vs “WT only”, Fig. 5b). Our results thus suggest
that ATF3 not only increased its level, but also altered its
genome binding in response to DNA damage.
We next addressed the question as to what changes in
gene expression the altered ATF3-binding would cause
under the DNA damage condition. Treating HCT116
cells with CPT for 4 h resulted in an increase in expres-
sion of 733 genes and a decrease in expression of 1095
genes (fold > 1.5, p < 0.05) (Fig. 5f ). 1,300 (71.1 %) of
these altered genes were bound by ATF3 after DNA
damage (Fig. 5g), and thus were more likely regulated by
ATF3. Interestingly, 82.9 % of ATF3-bound, CPT-
regulated genes were also bound by ATF3 before the
cells were treated with CPT (Fig. 5g), suggesting that
ATF3 were pre-loaded on the genomic sites for gene
regulation under stressed conditions. However, stressed
ATF3 appeared to bind these sites more strongly than
the quiescent protein (Fig. 5h). Given that CPT equally
increased or decreased ATF3 binding on the “shared”
sites (see above), these results indicate that DNA dam-
age selectively promoted ATF3 to bind to genomic sites
associated with regulated genes.
To further determine the relationship between ATF3
binding and gene regulation under the stressed condi-
tion, we analyzed the gene expression data for ATF3
knockout cells, and generated a curated list of 93 genes
Fig. 4 Binding of ATF3 to active enhancers correlates with ATF3-regulated gene expression. a Heatmaps showing ATF3-regulated genes, and their
binding by ATF3 and p300. b qRT-PCR validation of genes differentially expressed between ATF3-wildtype and knockout cells identified by microarray.
c, d Validation of ATF3 binding to differentially-expressed genes by ChIP-qPCR. e ATF3 was localized in regions distal to TSS (>2 kb) of differentially-
expressed genes. f Representative genome browser views of co-localization of ATF3 and p300 in ATF3-regulatd genes. g ATF3 was localized in active
enhancers of ATF3-regulated genes. Error bars represents SD
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that were judged, with high confidence, as ATF3-
regulated genes in response to DNA damage (Additional
file 1: Figure S2D), based on (1) that fold changes before
and after the CPT treatment were significantly different
(p < 0.05, paired t-test) between ATF3-wildtype and
-knockout cells, (2) that the genes bound by ATF3 with a
small binding score (<10) and thus more likely to be de-
rived from experimental errors were excluded. Once
again, while 82 (88.2 %) of these genes had already been
bound by ATF3 under the basal condition, CPT further in-
creased ATF3 binding to these regulated genes, regardless
whether their expression was induced or repressed by
CPT (Fig. 5i and j). Interestingly, about a half (43, or 46 %)
of these genes contained one or more active enhancers
that were bound by both p300 and ATF3 (Fig. 5i), consist-
ent with our previous conclusion that ATF3 can bind to
active enhancers to regulate gene expression.
ATF3 collaborates with p53 in regulating target gene
expression
p53 is a master transcription factor that transactivates genes
(e.g., CDKN1A and BBC3, best known as p21 and PUMA,
respectively) essential for driving cellular responses (e.g., cell
cycle arrest and apoptosis) to DNA damage [34]. As ATF3
can bind p53 [16] and we also found that ATF3-bound
genes engage in the p53 signaling pathway (Fig. 2c), we
Fig. 5 DNA damage alters the ATF3-binding landscape for transcriptional regulation. a Venn diagram showing overlap of ATF3-binding peaks
between the basal (ATF3-WT) and the CPT-treated (ATF3-CPT) conditions. b Heatmaps and intensity plots showing alterations in the ATF3-binding
profile caused by DNA damage. c Intensity plots showing different enrichments of ATF3, p300, and histone markers between CPT-induced and
decreased peaks. d Distribution of ATF3-binding sites under basal (ATF3-Ctrl) and stressed (ATF3-CPT) conditions. e Venn diagram showing overlaps of
ATF3 peaks and p300 peaks under the CPT-treatment condition. f Heatmaps showing CPT-regulated genes. g Heatmaps of ATF3-binding sites associated
with CPT-regulated genes showing that ATF3 was pre-loaded on most of these genes before stress. h Intensity plot showing that ATF3 binding to CPT-
regulated genes was increased by the CPT treatment. i Heatmap showing ATF3-regulated genes under the DNA damage condition were pre-bound by
ATF3. j Intensity plot showing that DNA damage increased ATF3 binding to ATF3-regulated genes
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sought to determine how ATF3 interacts with p53 at gen-
omic sites to regulate gene expression in response to CPT-
induced DNA damage. We first profiled global p53 binding
by subjecting CPT-treated HCT116 cells to ChIP-seq
analysis. We identified 1,412 p53-binding peaks (Fig. 6a), a
number which was low but within the same range (from
743 to 4,785) as other reports [35–37]. These identified
binding sites included 3 previously-characterized p53-
Fig. 6 Co-localization of ATF3 and p53 in genomic sites regulates gene expression in the DNA damage response. a Venn diagram showing the
overlap between ATF3 peaks and p53 peaks under the DNA damage condition. b Genome browser views of p53 binding to several well-characterized
p53 target genes. c Binding of p53 to indicated sites was validated by independent ChIP-qPCR assays. d Genome browser views of co-localization of
ATF3 and p53 in representative genomic sites. e ATF3 and p53 were co-localized in genomic sites as demonstrated by re-ChIP assays. HCT116 cells
treated with 1.5 μM of CPT for 4 h were first subjected to ChIP using the ATF3 antibody. The chromatin precipitated by the ATF3 antibody was then
eluted from agarose beads, and subjected to the second round of ChIP using the p53 antibody. qPCR assays were used to quantitate re-ChIPed DNA.
f Venn diagram showing the overlap of p53-binding sites containing the p53 motif or the ATF3 motif. g The ATF3 peak score correlated with the p53
peak score in the sites co-localized by ATF3 and p53. h ATF3 binding was often decreased in p53-knockout cells. p53-wildtype and knockout (p53-KO)
HCT116 cells were subjected to ChIP-qPCR to measure binding of ATF3 to the indicated sites. i p53 binding was decreased in ATF3-knockout cells.
ATF3-wildtype and knockout (ATF3-KO) HCT116 cells were subjected to ChIP-qPCR to measure binding of p53 to the indicated sites. j Expression of
p53 target genes was repressed in ATF3-KO cells. Indicated cells were treated with 1.5 μM of CPT for qRT-PCR assays. ATF3 binding to these genes
before and after CPT treatments in ATF3-WT cells were shown in Additional file 1: Figure S3
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binding sites in the CDKN1A enhancer and promoter re-
gions (site A, C and D, respectively) (Fig. 6b) [35], and sites
localized in the promoters of well-characterized p53 target
genes MDM2, BBC3 and BAX (Fig. 6b). These p53-binding
sites were validated by independent ChIP-qPCR assays
(Fig. 6c). Consistent with the notion that ATF3 is a p53
regulator [16], we found that ATF3 bound to 23.5 % (332)
of p53-binding sites (Fig. 6a), including the CDKN1A site A
(but not site C and D), and the sites associated with
GADD45A, MDM2 and IGFL3 (Fig. 6d). Using re-ChIP as-
says, we confirmed that ATF3 was co-localized with p53 at
Site A, but not Site C, of CDKN1A, and other tested gen-
omic sites associated with GADD45A, MDM2, IGFL3,
GSN, and BBC3 (Fig. 6e). Of these ATF3/p53 co-localized
sites, 61 only carried a p53 motif, 7 only carried an ATF3
motif, and 63 harbored both motifs (Fig. 6e; Additional file
2: Table S1). Given that ATF3 can directly bind p53 [16],
co-localization of ATF3 with p53 at genomic sites might be
owing to p53-mediated recruitment of ATF3 to sites con-
taining the p53 motif, and/or ATF3-mediated recruitment
of p53 to sites harboring the ATF3 motif. Indeed, we found
a strong correlation between the ATF3-binding score and
the p53 peak score at these genomic sites (r = 0.8170,
Fig. 6g). Moreover, p53 depletion dramatically impaired
ATF3 binding to 5 out of 7 tested p53-motif-only sites
(Fig. 6h). Of note, although p53 was previously shown to be
required for ATF3 induction by DNA damage caused by γ-
irradiation [38], we did not see decreased ATF3 expression
in p53-knockout cells under our experimental condition
(data not shown). The reason why p53 knockout did not
decrease ATF3 binding to the CDKN1A Site A and the
GDF15 p53-binding site that lacked the ATF3 motif was
unclear, but other TFs might recruit ATF3 to these sites.
Interestingly, p53 binding to the sites containing only the
ATF3 motif was significantly decreased by ATF3 knockout
as well (Fig. 6i), suggesting that ATF3 could also recruit
p53 to genomic sites that do not contain a p53 motif. Thus,
the ATF3-p53 interaction might expand the list of genes
that can be regulated by p53. Interestingly, 19.5 % (58/297)
of the ATF3/p53 co-localized sites, including the site associ-
ated with CDKN1A, BBC3 and GDF15, were also enriched
with p300, suggesting that many of these sites were active
enhancers and thus the ATF3-p53 interaction on genomic
sites were likely functional. Indeed, we demonstrated that
knockout of ATF3 expression impaired CPT-induced
CDKN1A, BBC3, and GDF15 expression (Fig. 6j). There-
fore, our results indicate that ATF3 could interact with p53
at genomic sites thereby regulating gene expression in the
DNA damage response.
Discussion
It is often shown that ATF3 binds the ATF/CRE cis-acting
element localized in gene promoters and regulate expres-
sion of genes associated with human diseases [12–14]. We
carried out this study in light of the fact that a genome-
wide ATF3-binding profile in the human genome was
lacking. Employing engineered ATF3-knockout cells as
the specificity control, we identified 33,681 specific ATF3-
binding sites across the human genome under the basal
condition. Although this number was surprisingly large
given that the basal ATF3 expression level was low, it was
comparable to 22,521 sites identified in mouse dendritic
cells [39]. As 81.7 % of the ATF3-binding sites contained a
known ATF3 motif (Fig. 2e) [40], ATF3 might directly
bind a majority of these sites. It was thus likely that the
low level of constitutively-expressed ATF3 was sufficient
to bind most of available sites in the genome. Interestingly,
ATF4, a family member sharing the same binding motif
with ATF3, binds only 1,210 sites in the mouse genome
[39]. While this difference might be owing to different
DNA-binding affinity, interactions with other transcrip-
tion regulators could poise ATF3 for a higher level of gen-
ome binding. The latter possibility is supported by the fact
that ATF3 differs from ATF4 in its ability of interacting
with other proteins [25]. It is worth noting that the ATF3
genome-occupancy level is lower than that of pioneer fac-
tors, which often bind more than 50,000 genomic sites [39],
but significantly higher than that of most of gene-specific
TFs (e.g., p53) that generally occupy a few thousands of
genomic sites (Fig. 6a). It is thus tempting to hypothesize
that ATF3 serves as a molecular beacon, or “primer factor”,
that binds genomic sites subsequent to binding of pioneer
factors, and directs other TFs or transcription co-regulators
to appropriate genomic sites upon stimulation [39]. This
hypothesis was partly supported by the findings that ATF3
directly interacts with many TFs (e.g., p53, p63, AR, Sp1)
[16, 21, 26, 41] and histone modifying enzymes (e.g., Tip60
and HDAC) [17, 22]. Importantly, while the GO analysis re-
vealed that the ATF3-bound genes were associated with
cellular response to stress under the basal condition
(Fig. 2c), we found that the genes whose expression was
regulated by DNA damage were often pre-bound by ATF3
(Fig. 5g). Thus, like the transcription factor p63 [42], ATF3
might bookmark genes for transcriptional regulation. In
this regard, it is likely that ATF3 recruits diverse sets of TFs
to genomic sites pre-bound by ATF3 upon varying stimuli,
thereby regulating gene expression and mounting rapid, ap-
propriate responses to varying cellular stresses. However,
DNA damage-induced changes in ATF3 binding were more
dynamic than what the “primer-factor” hypothesis suggests
[39]. DNA damage not only increased the number of ATF3
binding sites by 1 fold, but abolished up to one-fifth of the
basal binding events (Fig. 5b). In addition, CPT increased
ATF3 binding to some genomic sites but decreased its
binding to almost equal numbers of other sites. While
stress-induced loss of genomic binding has also been re-
ported for other stress-inducible TFs (e.g., JunB) [39], the
decrease in ATF3 binding to a substantial number of
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genomic sites argues against the notion that the dynamic
changes in ATF3 binding was a mere consequence of ele-
vated ATF3 expression induced by DNA. As DNA damage
can alter chromatin structure [43–45], it might allow access
of some genomic sites to, while shielding other sites from,
ATF3. Interestingly, the CPT treatment appeared to pro-
mote ATF3 to bind to sites distal to TSS (Fig. 5d). While
the exact mechanism remains elusive, it might be that the
epigenetic environments where the distal sites reside are
favorable for TF binding. Indeed, these distal sites often co-
incide with p300/H3K27ac-enriched active enhancers
(Fig. 3d), which are known to have lower nucleosomal
density [5].
Like other TFs [36, 42], binding of ATF3 to the regula-
tory region of a gene did not always result in a change in
gene expression. Indeed, although ATF3 bound more
than 10,000 genes, a complete loss of ATF3 expression
only altered expression of a small number of genes
under both the quiescent and the stressed condition.
While RNA-based assays (e.g., microarray and RNA-seq)
may not serve as accurate measurements of transcrip-
tion activity [42], other TFs capable of binding the same
motifs (e.g., JunB) [39] might compensate for ATF3 loss.
Interestingly, the ATF3-binding sites often contained
motifs of other TFs in addition to the ATF3 motif
(Fig. 2), suggesting that ATF3 might act in concert with
other TFs to regulate gene expression. Our results also
indicate that ATF3 can activate or repress gene expres-
sion depending on gene context. While the location and
motif composition of the ATF3-binding site did not ap-
pear to determine whether ATF3 activates or represses
gene expression (Additional file 1: Figure S1D and S1E),
it is very likely that the epigenetic environment sur-
rounding the ATF3-binding sites determine the availabil-
ity of transcription co-activators (like Tip60), or
transcription co-repressors (e.g., HDAC), which conse-
quently transactivate or repress expression of ATF3-
bound genes. Thus, the early notion that ATF3 homodi-
mers and heterodimers respectively repress and activate
transcription appears oversimplified and misleading.
An important finding from this study is that ATF3 bound
to 37 % of genomic sites that were bound by p300 and
characterized by high levels of H3K27ac under the basal
condition (Fig. 3b). These genomic sites are defined as ac-
tive enhancers and have been shown to contain functional
regulatory elements that drive proximal gene expression
during embryonic development [3, 4]. Interestingly, DNA
damage increased the percentage of active enhancers bound
by ATF3 to 57.6 %. Moreover, although ATF3 binding alone
was not sufficient to regulate transcription, most of genes
regulated by ATF3 appeared localized proximal to ATF3-
bound active enhancers (Fig. 4). This strong correlation
between TF binding to active enhancers and the regulation
of gene expression was not without precedent. The
transcription factor p63, for instance, was recently shown
to bind H3K27ac-enriched active enhancers, and the bind-
ing correlates with dynamic gene expression regulated by
p63 during epidermal differentiation [42]. As active en-
hancers often contain a cluster of motifs allowing for
binding by multiple TFs, it is likely that these TFs collab-
oratively interact with the basal transcription machinery
in core promoters to regulate gene expression. Therefore,
the observed correlation between enhancer binding and
transcriptional regulation is consistent with our notion
that ATF3 needs to cooperate with other TFs to regulate
gene expression.
The tumor suppressor p53 drives a transcription pro-
gram for eliciting diverse cellular responses to DNA
damage. Previously, we reported that ATF3 can activate
p53 by binding and directly blocking its ubiquitination
[16]. We also found that ATF3 can induce p53 activation
by promoting the activity of a histone acetyltransferase
Tip60 and the subsequent activation of ATM [22]. In
this study, we revealed an additional mechanism by
which ATF3 regulates p53, i.e., co-localization with p53
at genomic sites. Indeed, we found that ATF3 was co-
localized with p53 at more than 20 % of p53-binding
sites identified by ChIP-seq (Fig. 6a). As ATF3 can inter-
act with p53 [16], such co-localization might be a conse-
quence of p53-mediated ATF3 recruiting (Fig. 6h), or
vice versa (Fig. 6i). On the other hand, some co-
localized genomic sites contained both the p53 and the
ATF3 motif, and thus could be bound by p53 and ATF3
simultaneously. Regardless, close proximity between
ATF3 and p53 at genomic sites might directly alter p53
conformation thereby regulating the p53 transcriptional
activity (Fig. 6j). Our results are supported by a recent
report, which carried out ATF3 ChIP-chip assays and
shows binding of ATF3 to promoters of many known
p53 target genes [46]. However, Our study indicates that
a large number of co-localized sites were far beyond pro-
moter regions [47] and were also often bound by p300.
Therefore, the genomic co-localization of ATF3 and p53
serves as an additional mechanism for fine tuning p53
activity in the DNA damage response.
Conclusions
Our results indicate that ATF3 likely preoccupies gen-
omic sites regulatory for genes involved in the cellular
stress response, and thus bookmarks these sites for tran-
scriptional regulation under basal and stressed
conditions.
Methods
Cell culture and generation of ATF3-knockout cells
HCT116 wild-type and p53-knockout cells (obtained
from Bert Vogelstein) were cultured in McCoy’s 5A
medium supplemented with 10 % fetal bovine serum.
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H1299 cells and 293 T cells were cultured in RPMI 1640
and DMEM medium, respectively. We knocked out
ATF3 expression in HCT116 cells using a rAAV-based
approach [23]. Briefly, left and right homology arms
flanking a small region (22 bp) in the exon 3 of ATF3
were amplified by PCR, and sequentially ligated into
pAAV-TK-Acceptor [23] via restriction enzyme diges-
tion. The resulted plasmid was then transfected into
AAV-293 cells for rAAV packaging using the AAV
Helper-free System (Agilent) following the manufac-
turer’s protocol. For viral infections, HCT116 cells in
60 mm dishes were incubated with 2 ml of viral super-
natant overnight, followed by re-suspension in medium
containing 500 μg/ml of G418 for selection. Genomic
DNAs were then prepared from resistant single clones
as describe previously [48], and used for PCR to identify
targeted clones. To remove the inserted selection gene,
targeted clones in 24-well plates were transfected with a
Cre-expression plasmid. Single clones regaining G418
sensitivity were accordingly identified, and subjected to
the 2nd round of genome editing to knock out the 2nd
ATF3 allele as describe above. The sequences of primers
used in this report are available upon request.
Chromatin immunoprecipitation
Chormatin immunoprecipitation was performed essen-
tially as described previously [49]. Briefly, cells (2 × 107)
treated with or without 1.5 μM of CPT for 4 h were
cross-linked with 1 mM of di(N-succinimidyl) glutarate
(DSG) for 45 min, followed by 1 % formaldehyde for
10 min at room temperature. After treating with
0.125 M of glycine for 5 min, cells were resuspended in
10 ml of Solution I (10 mM Hepes-KOH, pH7.5, 10 mM
EDTA, 0.5 mM EGTA, and 0.75 % Triton X-100), and
incubated at 4 °C for 10 min. Cells were further incu-
bated with 10 ml of Solution II (10 mM Hepes-KOH,
pH7.5, 200 mM NaCl, 1 mM EDTA, and 0.5 mM
EGTA) at 4 °C for 10 min before lysed in cold FA lysis
buffer (50 mM Hepes-KOH, pH7.5, 140 mM NaCl,
1 mM EDTA, 1 % Triton X-100, 0.1 % sodium deoxy-
cholate, and proteinase inhibitors). Chromatin was
sheared by sonication using Bioruptor to an average
fragment size of 500 bp, and then incubated with 2 μg of
the antibody (ATF3, sc-188; p53, sc-126; p300, sc-585)
or normal IgG (rabbit, sc-3888; mouse, sc-2025) pur-
chased from Santa Cruz, at 4 °C overnight. Immuno-
complexes were precipitated with 30 μl of ssDNA-
protein A/G agarose (Millipore) at 4 °C for 2 h, and se-
quentially washed with Buffer I (50 mM Tris–HCl,
pH8.0, 150 mM NaCl, 1 % SDS, 0.5 % sodium deoxycho-
late, 1 % NP 40, and 1 mM EDTA), Buffer II (buffer I
with 500 mM NaCl), Buffer III (50 mM Tris–HCl,
pH8.0, 250 mM LiCl, 0.5 % sodium deoxycholate, 1 %
NP 40, and 1 mM EDTA), and TE buffer (50 mM Tris–
HCl, pH8.0, and 1 mM EDTA). Bound chromatin was
eluted with 0.3 ml of Elution buffer (50 mM Tris–HCl,
pH8.0, 1 % SDS, and 1 mM EDTA). After reversal of
crosslinking, RNase A and Proteinase K was added, and
DNA was purified by phenol extraction and ethanol pre-
cipitation. For re-ChIP assays, chromatin immunopreci-
pitated with the ATF3 antibody was eluted in 0.15 ml of
Elution buffer, and then diluted by 20 times with re-
ChIP buffer (20 mM Tris–HCl, pH8.0, 150 mM NaCl,
1 % Triton X-100, and 2 mM EDTA), followed by incu-
bation with the p53 antibody as described above.
ChIP-seq and data analysis
ChIP-seq libraries were prepared according to standard
protocols using Biosicentific’s DNA Sample Kit
(cat#514101) [50]. Libraries were sequenced using Illumina
Hi-Seq platforms. Sequence reads were aligned to the
Human Reference Genome (assembly hg19) using
Burrows-Wheeler Alignment (BWA) Tool Version 0.6.1.
Peak identification, overlapping, subtraction and feature an-
notation of enriched regions were performed using Hyper-
geometric Optimization of Motif EnRichment suite
(HOMER). Heatmaps and intensity plots of peaks were
generated by Perl script, R and/or java Treeview. HOMER
was used to check motif enrichment.
Microarray data analysis
Total RNA was prepared using Agilent Total RNA Isola-
tion Mini Kit (cat# 5185–6000). Microarray expression
profiling was performed using HumanHT-12 v 4.0 Expres-
sion BeadChip (Illumina). Data were preprocessed and
normalized by GenomeStudio. Differentially expressed
genes were identified by Bioconductor limma package and
GenePattern. Heatmap view of differentially expressed
genes was created by Cluster and Java Treeview. GO term
enrichment was determined using DAVID.
Western blotting and quantitative PCR
Western blotting assays were performed as described
previously [16]. In brief, cells were lysed in RIPA buffer
containing 50 mM Tris–HCl, pH 7.4, 1 % Nonidet P-40,
0.25 % sodium deoxycholate, 150 mM NaCl, 1 mM
EDTA, 1 mM PMSF, and 1 mM NaF, 1 mM Na3VO4,
and protease inhibitor cocktail (Roche), and then
resolved in SDS-polyacrylamide electrophoresis for im-
munoblotting. Quantitative PCR assays were carried out
using SYBR Green as described elsewhere [49].
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